TAE Life Sciences
PrivateLast Round
Series C
Jun 3, 2024
Est. Valuation
$400M
Total Funding Raised
$40M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
TAE Life Sciences is a biotechnology company that develops biologically targeted radiation therapies utilizing Boron Neutron Capture Therapy (BNCT) to treat invasive and challenging cancers.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Precision Medicine, Medical Imaging
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Usage-Based SaaS
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TAE Life Sciences Comparables
Compare TAE Life Sciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Dawon Medax | 85% | |
| Neutron Therapeutics | 84% | |
| Neuboron Medical Group | 83% |
TAE Life Sciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 3, 2024 | ||||
| Series B | Jun 2, 2020 | ||||
| Series A | Mar 12, 2018 |
TAE Life Sciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Rising Tide Fund | Series B, Series A |
| ARTIS Ventures | Series B, Series A |
| Big Sky Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Monthly visitors increased 37% MoM.
- Apr 1, 2026
CNAO identified as a key deployment site.
Recent news
Latest coverage and updates
- attends_eventSep 25, 2026
TAE Life Sciences attended event ASTRO 2026 annual meeting on Sep 24th '26.
- recognized_asSep 10, 2026
TAE Life Sciences recognized as ISO 13485 certification on Sep 10th '26.
TAE Life Sciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about TAE Life Sciences's valuation, stock price, and market status.
Is TAE Life Sciences a public or private company?
TAE Life Sciences is a private company.
What is the current stock price of TAE Life Sciences?
TAE Life Sciences is a private company with no public stock price. No recent secondary market data is available.
How much is TAE Life Sciences worth (valuation)?
TAE Life Sciences's valuation is estimated at $400.0M based on funding round data.
Can I buy TAE Life Sciences stock?
TAE Life Sciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was TAE Life Sciences's last funding round?
TAE Life Sciences's most recent funding round was Series C on June 3, 2024.
Who are the main investors in TAE Life Sciences?
Key investors in TAE Life Sciences include ARTIS Ventures.
Will TAE Life Sciences IPO soon?
No public IPO plans have been announced for TAE Life Sciences.
How can I track TAE Life Sciences secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor TAE Life Sciences's secondary market activity and sign up for updates.